GSK PLC SEC Filings

GSK plc repurchased 235,000 ordinary shares of 31¼ pence each on 17 December 2025 as part of its existing share buyback programme, acting through BNP Paribas SA. The shares were bought between 1,824.00p and 1,850.00p per share, with a volume-weighted average price of 1,841.56p, and will be held as treasury shares.

After this transaction, GSK will hold 239,551,577 ordinary shares in treasury and have 4,075,889,506 ordinary shares in issue (excluding treasury shares), giving the same number of voting rights. The percentage of voting rights attributable to the treasury shares is 5.88 per cent.

GSK plc reports that the US Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients aged 12 and older.

The ultra-long-acting biologic is given just twice a year and, in the phase III SWIFT-1 and SWIFT-2 trials, reduced annualised asthma exacerbations by 58% and 48% versus placebo over 52 weeks, on top of standard care. A pooled analysis showed a 72% reduction in clinically significant exacerbations requiring hospital or emergency visits, with a side-effect profile similar to placebo.

GSK notes that around 2 million Americans live with severe asthma and many remain uncontrolled, and sees Exdensur as a way to offer longer-lasting protection with fewer injections.

GSK plc reports that on 16 December 2025 it repurchased 230,000 of its ordinary shares of 31¼ pence each as part of its ongoing share buyback programme. The shares were bought through BNP Paribas SA under a non-discretionary agreement, at prices between 1,816.50p and 1,850.00p, with a volume-weighted average price of 1,834.71p per share, and will be held as treasury shares.

Following this transaction, GSK holds 239,316,577 ordinary shares in treasury and has 4,076,124,506 ordinary shares in issue excluding treasury shares. The total number of voting rights is 4,076,124,506, and the percentage of voting rights attributable to treasury shares is 5.87 per cent, providing a reference point for shareholders assessing disclosure thresholds. Since 30 September 2025, GSK has purchased 13,851,733 ordinary shares under this programme, with trades executed on London Stock Exchange and Cboe Europe venues.

GSK plc reports that UK regulators have granted marketing authorisation for Exdensur (depemokimab), the first ultra-long-acting biologic with twice-yearly dosing for respiratory disease. In the UK it is approved as an add-on treatment for severe asthma with type 2 inflammation in patients 12 and older and as add-on therapy for adults with severe chronic rhinosinusitis with nasal polyps when steroids or surgery are not enough.

The SWIFT phase III asthma trials showed a 54% reduction in clinically significant exacerbations over 52 weeks and a 72% reduction in attacks leading to hospitalisation or emergency visits versus placebo. ANCHOR phase III trials in nasal polyps showed meaningful improvements in polyp size and nasal obstruction, and safety was similar to placebo. This is the first global approval for Exdensur, with regulatory decisions expected in the US, Japan, EU and China starting in December 2025 through H1 2026.

GSK plc reports that on 15 December 2025 it repurchased 230,000 ordinary shares of 31¼ pence each under its existing share buyback programme, acting through BNP Paribas SA. The shares were bought at prices between 1,810.50p and 1,838.00p, with a volume-weighted average price of 1,825.73p, and will be held as treasury shares.

The company states that since 30 September 2025 it has purchased 13,621,733 ordinary shares under this programme. After this latest transaction, it holds 239,086,577 shares in treasury and has 4,076,354,506 ordinary shares in issue, which is also the total number of voting rights. GSK confirms that the voting rights attributable to treasury shares are 5.87 per cent, a reference point for shareholders monitoring disclosure thresholds.

GSK plc, through its wholly owned subsidiary Glaxo Group Limited, reported buying 1,470,000 ordinary shares of Wave Life Sciences Ltd. on 12/11/2025 at a price of $19 per share.

After this transaction, the reporting person beneficially owned 18,245,691 Wave Life Sciences ordinary shares, held indirectly via Glaxo Group Limited. The report reflects GSK plc’s role as a shareholder in Wave Life Sciences rather than a change in GSK plc’s own financial results.

GSK plc reports that it has repurchased 230,000 of its ordinary shares of 31¼ pence each on 12 December 2025 through BNP Paribas SA, under a non-discretionary agreement that forms part of its existing share buyback programme announced on 30 September 2025. The shares were bought at prices between 1,816.00p and 1,837.00p, with a volume-weighted average price of 1,827.59p, and will be held as treasury shares rather than being cancelled.

Since 30 September 2025, GSK has repurchased 13,391,733 ordinary shares. After this latest transaction, it holds 238,856,577 ordinary shares in treasury and has 4,076,584,506 ordinary shares in issue, which is also the total number of voting rights. The company states that treasury shares now represent 5.86 per cent of the voting rights, a figure shareholders can use when calculating disclosure thresholds for their holdings.

GSK plc reported that Europe’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of depemokimab for two uses: severe asthma with type 2 inflammation and severe chronic rhinosinusitis with nasal polyps (CRSwNP). If approved, depemokimab would be the first ultra-long-acting biologic for respiratory disease in the EU, given as just two doses a year. The opinion is based on four phase III trials showing a 54% reduction in clinically significant asthma exacerbations over 52 weeks and a 72% reduction in exacerbations requiring hospital or emergency department care, versus placebo plus standard treatment. In CRSwNP, depemokimab improved nasal polyp size and nasal obstruction scores. The European Commission decision is expected in Q1 2026, and depemokimab is not yet approved anywhere.

GSK plc reported that the European Medicines Agency’s CHMP has issued a positive opinion recommending approval of Nucala (mepolizumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils who are already on inhaled triple therapy. The opinion is based on the phase III MATINEE trial, where Nucala reduced the annual rate of moderate or severe COPD exacerbations versus placebo when both were added to triple therapy, with a rate ratio of 0.79 and similar overall adverse event rates between groups.

A pre-defined secondary analysis showed Nucala also lowered exacerbations that led to emergency department visits and/or hospitalisations compared with placebo. Nucala is already approved in Europe for four eosinophilic and type 2 inflammatory conditions and received US approval for COPD in May 2025. The European Commission decision on this new COPD indication is expected in Q1 2026, which could expand treatment options for patients whose disease remains uncontrolled.